Search
for
Sort by
Research 601–630 of 1000+
- Upadacitinib for the treatment of alopecia areata – A case report
- Efficacy of mesalazine in children with moderate to severe alopecia areata: case series of 18 patients
- ISID1108 - Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata.
- 1108 Comparison of ruxolitinib and a collagen-targeted PTH-based hair cycle stimulant on hair follicle counts and hair growth in the C3H/HeJ engrafted mouse model of alopecia areata
- Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
- Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak
- JAK inhibitors for alopecia areata: a systematic review and meta‐analysis
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Alopecia Areata: Current Treatments and New Directions
- Scoping Review on the Use of Drugs Targeting JAK/STAT Pathway in Atopic Dermatitis, Vitiligo, and Alopecia Areata
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- The Safety and Efficacy of Tofacitinib in 24 Cases of Pediatric Rheumatic Diseases: Single Centre Experience
- Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases
- Alopecia Areata: An Update on Treatment Options for Children
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Upadacitinib for Successful Treatment of Alopecia Universalis in a Child: A Case Report and Literature Review
- Under Development JAK Inhibitors for Dermatologic Diseases
- Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
- Efficacy and safety of tofacitinib therapy in Asian patients with severe alopecia areata
- Factors influencing alopecia areata treatment decisions: A qualitative assessment
- Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19
- Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
- Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
- Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
- Refractory alopecia in lupus treated with tofacitinib — a case-based review
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
- Drug Repurposing of Voglibose, a Diabetes Medication for Skin Health
- Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study
- A retrospective analysis of disease epidemiology, comorbidities, treatment patterns, and healthcare resource utilization of alopecia areata in the United Arab Emirates using claims database